We found that advanced stage CRC concomitant with VAV3 overexpression had a significantly lower 10-year overall survival rate than advanced stage CRC without VAV3 overexpression (Figure 2c, P = 0.049), whereas early stage CRC (stages I and II) had a better 10-year overall survival rate, regardless of the VAV3 expression status (Figure 2d, P = 0.526). Here, VAV3 is linked to colorectal carcinoma.